MedTrace Logo

The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective.

NCT06993662 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2026-05-07

No results posted yet for this study

Summary

The combination of pharmacotherapy and individual cognitive behavioral therapy in a private practice.

Conditions

Interventions

COMBINATION_PRODUCT

Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression.

The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by anxiety disorders and depression.

COMBINATION_PRODUCT

Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD

The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by PTSD

COMBINATION_PRODUCT

Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.

The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.

COMBINATION_PRODUCT

Group D.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by bipolar disorder

The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil) antidepressants (SSRI, SNRI), mood stabilizers (lithium, depakine), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by bipolar disorder.

COMBINATION_PRODUCT

Group E. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders

The combination of pharmacotherapy (anxiolytics(tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders.

COMBINATION_PRODUCT

Group F.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by personality disorders

The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics) and individual cognitive behavioral psychotherapy by personality disorders.

Sponsors & Collaborators

  • Rakitzi, Stavroula

    lead OTHER

Principal Investigators

  • Dr. Stavroula Rakitzi, PhD · Private Practice

  • Dr. Polyxeni Georgila, M. D. · Private Practice

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-02
Primary Completion
2027-12-20
Completion
2027-12-20
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06993662 on ClinicalTrials.gov